Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial.

ABSTRACT:

Importance

It is unclear whether ticagrelor or prasugrel hydrochloride is superior for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI).

Objective

To assess the safety and efficacy of ticagrelor vs prasugrel for patients with ACS treated with PCI.

Design, setting, and participants

A prespecified analysis was performed of a postrandomization subgroup of 3377 patients who presented with ACS and were treated with PCI in the investigator-initiated, multicenter, phase 4, open-label Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 5 randomized clinical trial, conducted from September 1, 2013, to February 28, 2018. Statistical analysis was performed from September 1, 2020, to January

SUBMITTER: Coughlan JJ 

PROVIDER: S-EPMC8246339 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature